XML 45 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9
DISCONTINUED OPERATIONS
 3 Months Ended
Mar. 31, 2015
Discontinued Operations  
DISCONTINUED OPERATIONS
9. DISCONTINUED OPERATIONS

 

On August 10, 2012, the Company entered into an agreement with Sinclair Pharmaceuticals Limited (“Sinclair”) to terminate, effective September 30, 2012, the distribution agreements relating to the promotion and sale of Xclair®, Numoisyn® Lozenges and Numoisyn® Liquid (collectively, the “ALIGN products”).

 

Product revenue, cost of goods sold and selling, general and administrative costs related to the promotion and sale of the ALIGN products have been reclassified from operating results from continuing operations to income from discontinued operations in the consolidated statement of operations for all periods presented as follows (in $000s):

 

    Three Months Ended
March 31,		  
    2014     2015  
Interest income   $ 13     $ —  
Income tax on discontinued operations     5       —  
Net income from discontinued operations   $ 8     $ —  

 

The assets and liabilities associated with product promotion and sales have been classified within assets and liabilities of discontinued operations in the accompanying consolidated balance sheets (in $000s):

 

    December 31,
2014		     March 31,
2015		  
             
Current assets of discontinued operations:                
Short term portion of minimum royalty arrangement receivable, net   $ 96     $ 72  
Returns indemnification receivable     75       75  
Total current assets of discontinued operations   $ 171     $ 147  
                 
Current liabilities of discontinued operations:                
Returns provision   $ 75     $ 75  
Total current liabilities of discontinued operations   $ 75     $ 75